IMPAACT P1107 Team Presents First Known Case of a Woman with HIV Remission
At CROI 2022, the IMPAACT P1107 protocol team reported the first known case of a woman with HIV remission following a CCR5Δ32 stem cell transplant for treatment of acute myelogenous leukemia.
P1107 is multi-center observational study that will describe the outcomes of up to 25 participants from the US living with HIV, ages 12 months and older, who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer, hematopoietic disease, or other underlying disease. The study began in 2015 and has been conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), StemCyte, and the AIDS Clinical Trials Group (ACTG).
The study participant, a U.S. woman who identifies as mixed race, stopped antiretroviral therapy (ART) 37 months post-transplant. With the exception of transient trace levels of HIV DNA detected 14 weeks after stopping ART, no HIV has been detected for 14 months.
The Frontier Science Data Management team working on the P1107 study are Amanda Golner and Fred Bone.